U.S. Markets closed

Active Biotech AB (publ) (ACTI.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
1.0000+0.0090 (+0.91%)
At close: 05:29PM CET

Active Biotech AB (publ)

Scheelevägen 22
Lund 223 63
46 46 19 20 00

Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Ms. Helen Tuvesson Ph.D.Pres & CEO4.41MN/A1962
Mr. Hans KolamChief Financial OfficerN/AN/A1951
Dr. Erik VahtolaChief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.


Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.

Corporate Governance

Active Biotech AB (publ)’s ISS Governance QualityScore as of October 1, 2022 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.